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Prostate cancers are highly prevalent in the developed world, with inheritable risk contributing appreciably to tumour
development. Genomic heterogeneity within individual prostate glands and between patients derives predominantly from
structural variants and copy-number aberrations. Subtypes of prostate cancers are being delineated through the increasing use of
next-generation sequencing, but these subtypes are yet to be used to guide the prognosis or therapeutic strategy. Herein, we
review our current knowledge of the mutational landscape of human prostate cancer, describing what is known of the common
mutations underpinning its development. We evaluate recurrent prostate-specific mutations prior to discussing the mutational
events that are shared both in prostate cancer and across multiple cancer types. From these data, we construct a putative overview
of the genomic evolution of human prostate cancer.
GENOMIC EPIDEMIOLOGY
Prostate cancer is the most common cancer affecting men in the
developed world, accounting for 25% of all new cases of cancer in
males (Cancer Research UK, 2014). Of men diagnosed at the
current time, 84% are predicted to survive 10 or more years. The
incidence is strongly correlated with age, rates rising sharply from
166 per 100 000 men at age 55–59 years to an overall peak of 800
per 100 000 in the 75–79 years age group. Age-specific mortality
rates also rise sharply from age 55, with the highest mortality rates
in the 85þ age group.
A landmark study examining the difference in the concordant
occurrence of prostate cancer between monozygotic and dizygotic
twins has revealed that 42% of prostate cancer may be explained by
heritable risk—more than any other human cancer (Lichtenstein
et al, 2000). This analysis has been updated with an expanded
study population and more comprehensive statistical modelling to
reveal an average genetic heritability of 58% (Hjelmborg et al,
2014). The first germline risk variant was discovered through the
relationship of the BRCA2 gene and prostate cancer by the Breast
Cancer Linkage Consortium. They estimated that heritable BRCA2
mutations confer a fivefold increased risk of prostate cancer.
Similarly, BRCA1 mutations have also been shown to heavily
predispose to prostate cancer, with both causing more aggressive
disease and a worse prognosis (Eeles et al, 2014). Genome-wide
association studies have expanded the discovery of germline
genetic variants, in particular common low-risk polymorphisms,
such that B33% of familial risk in the European ancestry
population is now accounted for (Al Olama et al, 2014).
Most susceptibility loci confer only a small increase in risk, with
their effects acting multiplicatively.
GENOMIC HETEROGENEITY
Multiple tumour foci are commonly detected within prostates from
patients with prostate cancer, and comparison of the genomic
landscape in both inter-related and geographically distinct regions
within prostates has revealed independent tumour origins
in several studies (Svensson et al, 2011; Lindberg et al, 2013;
Cooper et al, 2015). More recently, whole-genome sequencing of
multiple metastatic sites from 10 tumours has revealed a common
clonal origin containing 40–90% of total mutations and the
majority of driver mutations (Gundem et al, 2015). These data
imply that metastases originate commonly from only one tumour
foci. Once a cell population has successfully metastasised there is
strong evidence of on-going clonal evolution that has enabled both
‘metastasis-to-primary’ and ‘metastasis-to-metastasis’ re-seeding
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(Gundem et al, 2015; Hong et al, 2015). It appears therefore that
tumour heterogeneity increases as mutagenic processes continue to
allow tumour clones to compete with one another within their
micro-environment. This heterogeneity will only appear to
decrease when an emergent tumour cell clone has mutated
sufficiently to confer local or distant metastatic potential, or is
able to survive cancer therapeutics. Phylogenetic trees can
reconstruct the genomic archaeology of multi-focal tumours and
may be described simplistically as linear, branched or independent
as depicted in Figure 1. Many prostate cancers have been shown to
have independent origins prior to development via a branching
evolution stemming from a dominant clone.
MUTATIONAL PROCESSES SHAPING THE CANCER
GENOME
Next-generation sequencing of somatic variants has enabled us to
catalogue the mutations that have arisen within cancers. Roughly
half of all prostatic tumours contain a fusion of E26 transforma-
tion-specific (ETS) family transcription factor genes with andro-
gen-responsive promoters, most commonly transmembrane
protease, serine 2 (TMPRSS2). At present this event defines the
main molecular subtype of prostate cancer. Point mutations are
believed to be less contributory in prostate carcinogenesis, with
exome sequencing discovering a relatively low mutational
frequency of 0.3–5 per Mb (Taylor et al, 2010; Barbieri et al, 2012;
Grasso et al, 2012). In a saturation analysis of point mutations,
small mutations across multiple tumour types, only four
significantly mutated genes were discovered from the prostate
cancer data set; SPOP (found in 10.1% of samples), TP53 (3.6%),
ATM (2.2%) and MED12 (3.6%; Lawrence et al, 2014). When the
prostatic data set was compared with cancer genes from the other
20 cancer types an additional two significantly mutated genes were
detected, FOXA1 (2.9%) and COL5A1 (2.2%).
The frequency of copy-number aberrations (CNAs) in prostate
cancer is significantly higher than that of point mutations,
suggesting carcinogenesis and progression is primarily the result
of chromosomal re-arrangements. CNA burden, defined as the
percentage of the genome affected by CNAs, has been shown to
correlate with tumour grade, biochemical recurrence and metas-
tasis of prostate cancer, with metastatic samples containing an
average CNA burden of 32%, compared with 5% in primary
disease (Baca et al, 2013; Hieronymus et al, 2014). CNA burden
was also shown to be an independent prognostic biomarker for
biochemical recurrence and metastasis after surgery and could
further stratify the probability of recurrence in intermediate
Gleason 7 prostate cancers (Hieronymus et al, 2014).
Curating CNAs to determine mechanistically which genes are
driving oncogenesis remains challenging, and is especially true when
large regions have been gained or lost. Whereas homozygous
deletions often occur focally, loss of heterozygosity (LOH) and gains
commonly affect large regions of the genome, and inferring which
target gene within that region has conferred cellular growth
advantage remains challenging. Pan-cancer analyses of somatic
CNAs, examining the similarities and differences between diverse
tumour types have added power to detect recurrent focal regions
within the genome, many of which are thought not to contain known
oncogenes or tumour suppressor genes (TSGs; Zack et al, 2013).
A recent pan-cancer analysis delineated mutational signatures
contributing to the genomic landscape (Alexandrov et al, 2013).
Furthermore, many of these signatures could be attributed to
distinct mutational processes that are complicit in oncogenesis. For
prostate cancer, signatures corresponding to aging and DNA
mismatch repair (MMR) deficiency were detected, with predomi-
nant NpCpG to NpTpG substitutions. The contribution of an
aging signature in prostate cancer comes is unsurprising given its
age-related epidemiology. The DNA MMR deficiency signature is
comprised of very large numbers of substitutions, together with
small insertions/deletions of bases that are characteristic of cancers
with defective DNA MMR and termed ‘microsatellite instability’.
Although germline variants of MMR genes are thought to
predispose to prostate cancer (Raymond et al, 2013), somatic
mutations have rarely been detected (Taylor et al, 2010). Despite
these findings, decreased expression of MMR genes appears
common (Chen et al, 2001) leading to the hypotheses that defects
in as yet unknown genes are deregulating the MMR pathway.
The contribution of germline variants and mutational processes
in the development of prostate cancer are summarised in the upper
portion of Figure 2. Prostate cancer can be delineated according to
ETS fusion status and their associated genomic aberrations, which
are discussed in the subsequent section. Non-ETS-specific muta-
tions may represent a convergent pathway to later stage disease
and subsequent castrate resistance. Some of these mutations occur
in genes closely involved in androgen receptor signalling and
prostatic growth, whereas others occur in oncogenic pathways
common to other cancer types. These pathways are discussed in
turn in subsequent sections of this review.
ETS FUSION-POSITIVE TUMOURS
Recurrent gene fusions involving the oncogenic ETS transcription
factors are found in roughly half of prostate-specific albumin-
screened prostate cancers. Balanced structural re-arrangements,
with specific abundance of ETS transcription factor gene fusions
correlate with early onset prostate cancer as opposed to ‘classical’
elderly onset prostate cancer (Weischenfeldt et al, 2013; Steurer
et al, 2014). The most common fusion links the TMPRSS2
androgen-responsive promoter and the transcription factor gene
ERG (Tomlins et al, 2007). Many other androgen-related genes
have since been discovered with fusion to other members of the
ETS family including ets variant 1 (ETV1), ets variant 4 (ETV4), ets
variant 5 (ETV5), and Friend leukaemia virus integration 1 (FLI1;
Tomlins et al, 2009).
The inter-dependence of chained chromosomal re-arrange-
ments, termed ‘chromoplexy’ has been commonly observed in ETS
family fusion-positive prostate cancer and may disrupt multiple
genomically distant cancer genes co-ordinately (Baca et al, 2013).
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Figure 1. Genomic heterogeneity in multi-focal prostate cancer. (A)
Schematic prostatic section with three foci of genomically distinct
prostate cancer. (B) Possible evolutionary trees from fertilised egg (FE)
to the three foci of prostate cancer: (1) linear evolution; (2) branched
evolution; (3) independent evolution.
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The precise mechanism by which this occurs has yet to be
elucidated fully, but it appears to represent an early or initiating
step (Svensson et al, 2011; Weischenfeldt et al, 2013). Significantly,
primary tumours may contain hundreds of rearrangements
including translocations, deletions, insertions and inversions (Berger
et al, 2011), contributing significantly to the overall CNA burden.
Whole-genome chromatin immunoprecipitation analyses have
shown that ERG can bind to AR downstream target genes, and
have suggested that ETS activation promotes epithelial-mesench-
yme transition and tumour-invasive properties (Tomlins et al,
2007; Massie et al, 2011). This is supported through concordance
analysis of TMPRSS2-ERG gene fusions in prostate adenocarci-
noma and its precursor, prostatic intraepithelial neoplasia (PIN).
Within the same tumour samples an association of ETS gene
family fusions is seen with progression from PIN to cancer (Carver
et al, 2009). The function of ETS fusions in cancer has been further
explored in mouse models where ERG expression results in the
development of PIN only in the context of the phosphoinositide-3-
kinase (PI3K) pathway activation (King et al, 2009), and
combination with other lesions such as AR overexpression or
PTEN loss leads to invasive adenocarcinoma (Carver et al, 2009).
Multiple studies have also confirmed the correlation of ETS
re-arrangements with PTEN inactivation as synergistic steps in
the development of prostate cancer (Chen et al, 2005; Carver
et al, 2009; King et al, 2009; Steurer et al, 2014).
Other aberrations associated with positive ETS status include
focal deletions at 3p14, representing an aggressive phenotype with
early PSA recurrence (Krohn et al, 2013). This focal deletion is
detected in B20% of primary and 30% of advanced prostate
cancers (Williams et al, 2014). Three putative TSGs have been
implicated in the deletion: FOXP1, RYBP and SHQ1, though the
precise mechanism by which these deletions act is not yet clear
(Taylor et al, 2010; Krohn et al, 2013).
The clinical significance of ETS re-arrangements in prostate
cancer is still not fully resolved. Data are conflicting; ETS fusions
have been reported as associated with both more aggressive and
more indolent disease; most likely reflected by heterogeneity in
study cohorts (Tomlins et al, 2009).
ETS FUSION-NEGATIVE TUMOURS
Speckle-type POZ protein (SPOP) mutations and deletions in the q
arm of chromosome 5 and 6 anti-correlated with ETS fusion-
positive tumours (Figure 2). SPOP is an E3 ubiquitin ligase
substrate-binding protein. Increased prevalence of these deletions
with age has been shown to be strictly limited to ETS-negative
cancers (Weischenfeldt et al, 2013). We discuss here known
mechanisms of oncogenesis and the clinical implication of these
mutations.
The most common SPOP point mutation in prostate cancer
involves the substrate-binding cleft of the gene. This is mutated in
6–15% of tumours across multiple independent cohorts, and may
define a distinct molecular subclass of ETS-negative prostate
cancer (Barbieri et al, 2012; Grasso et al, 2012). Functional studies
are now required to determine how these mutations relate to
known and possibly new pathways of oncogenesis. A recent study
of the changes in the ubiquitin landscape induced by prostate
cancer-associated mutations in SPOP highlighted stabilisation of
the oncogene DEK and subsequent promotion of prostate epithelial
cell invasion (Theurillat et al, 2014).
Deletions involving the chromodomain helicase DNA-binding
protein 1 gene (CHD1) locus at 5q21 are associated with ETS
fusion-negative tumours and occur in 10–25% of both primary and
metastatic tumours (Barbieri et al, 2012; Grasso et al, 2012). Point
mutations and rearrangements involving CHD1 have also been
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Figure 2. The putative genomic evolution of prostate cancer from normal epithelium to castrate-resistant, metastatic cancer. The pathological
stages of prostate cancer are depicted on the left hand side of the figure, with corresponding genomic mutations that equate to cancer
progression on the right. Cytobands are annotated according to which driver genes are most strongly implicated by the corresponding aberration.
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identified (Berger et al, 2011; Grasso et al, 2012). CHD1 alters gene
expression possibly by modification of the chromatin structure.
Prostate tumours with CHD1 deletion have been shown to contain
an excess of both CNAs and intra-chromosomal re-arrangements
(Baca et al, 2013).
Heterogeneous deletions of 6q12–q22 confer poor prognosis
across multiple outcome parameters (Kluth et al, 2013; Williams
et al, 2014). The mitogen-activated protein kinase kinase kinase 7
(MAP3K7) gene encodes TAK1 and is located at the peak of this
broad region. As TAK1 has a role in the signalling transduction
induced by TGF beta and morphogenetic protein, and controls a
variety of cell functions including transcription regulation and
apoptosis, it is reported as a strong candidate for the driver TSG
within this region.
PROSTATE DEVELOPMENT AND ANDROGEN
SIGNALLING
The homeodomain-containing transcription factor Nkx3.1 is a
putative tumour suppressor that has been shown to be a critical
regulator of prostate epithelial differentiation and stem cell
function in mouse models (Shen and Abate-Shen, 2010). Its gene,
NKX3.1 often undergoes LOH, often a consequence of whole-arm
allelic deletion of 8p, and is observed at high frequency in both ETS
fusion-positive and -negative prostate cancers. Downregulation of
Nkx3.1 appears early in prostate cancer and may act as a
‘gatekeeper’ event in cancer initiation (Baca et al, 2013). Although
the incidence of LOH increases with tumour grade, the other allele
remains unmutated with low levels of gene expression, leading to
the speculation that epigenetic modification has a significant role
in its downregulation (Shen and Abate-Shen, 2010).
The androgen receptor (AR) is a nuclear hormone receptor
whose signalling is central to normal and cancerous prostate
development (Shen and Abate-Shen, 2010). Blockade of the
androgen pathway remains the mainstay of non-surgical treatment
but only postpones the inevitable progression of disease. AR
binding is implicated in tumour initiation through close proximity
of AR-binding sites with re-arrangement break points (Berger et al,
2011), raising the possibility that distant genomic loci, bought
together in close physical contact by AR complexes are re-arranged
through transcriptional stress.
Genes believed to modulate AR activity and that are mutated in
prostate cancer include the nuclear receptor co-activator 2 gene
(NCOA2) and forkhead-box A1 (FOXA1). Mutations, as well as
focal and non-focal gains have been detected in NCOA2 that were
significantly correlated with elevated NCOA2 transcript levels
(Taylor et al, 2010). Non-castrate patients with primary tumours
harbouring NCOA2 mutation, overexpression or high-level ampli-
fication had significantly higher rates of recurrence (Taylor et al,
2010). FOXA1 is an AR cofactor that is recurrently mutated in both
primary and metastatic tumours (Barbieri et al, 2012). FOXA1
expression has been demonstrated to increase cellular proliferation
in the presence of androgen (Grasso et al, 2012), and may have a
role in the progression of castrate-resistant prostate cancer. Other
members of the forkhead-box family are located within regions
that are recurrently deleted and a putative role as tumour
suppressors has been suggested (Taylor et al, 2010).
There is a complex interaction between the AR and other
signalling pathways, for instance the PI3K pathway. These
interactions may help explain some mechanisms behind castrate
resistance. The AR itself undergoes gene amplification, point
mutations and alteration in splicing leading to constitutively active
variants. Amplification (46% of samples) and point mutations
(10% of samples) are reported in hormone refractory metastatic
tumours but these are infrequently found in localised prostate
cancer prior to implementation of therapy (Barbieri et al, 2012;
Grasso et al, 2012). These data infer that AR aberrations are
important as a mechanism for resistance to hormonal therapy
(Visakorpi et al, 1995). Recent data have concluded that different
tumour cell subclones within metastatic sites can carry indepen-
dent mutations associated with castrate resistance (Gundem et al,
2015). Commonly, AR copy number was demonstrated to have
increased at separate time points implicating continuing selective
pressure on the AR pathway. Furthermore, metastasis from half of
the patients studied underwent polyclonal seeding with the transfer
of multiple tumour clones between metastatic sites. In the majority
of those patients, subclones carrying mechanisms associated with
castration resistance were found to have re-seeded multiple sites.
GENERIC PATHWAYS
PI3K. PI3Ks are a family of enzymes involved in cellular functions
such as cell growth, proliferation, differentiation, motility, survival
and intracellular trafficking. Recurrent aberrations in the PI3K
pathway, in particular the PTEN gene, reinforce its central
importance in the pathogenesis of prostate cancer and confirm
interest in its potential for targeted therapy.
PTEN acts by dephosphorylating lipid-signalling intermediates
to deactivate PI3K-dependent signalling and its loss is associated
with age and ETS-positive status (Steurer et al, 2014). Deletions at
the PTEN gene locus occur in B40% of primary prostate cancers,
and inactivating mutations occur in another 5–10% (Barbieri et al,
2012; Grasso et al, 2012; Weischenfeldt et al, 2013). These events
are more common in advanced disease (Taylor et al, 2010; Grasso
et al, 2012), and a striking correlation between homozygous PTEN
deletion and survival has been documented (Reid et al, 2010).
The membrane-associated guanylate kinase, WW and PDZ
domain containing 2 (MAGI2) gene and Phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene
potentially also subvert PTEN and therefore PI3K activity. MAGI2
encodes a PTEN scaffolding protein that is recurrently disrupted
by balanced re-arrangements without any evidence of copy-
number loss (Berger et al, 2011). PIK3CA has been reported to
undergo amplifications and activating point mutations in B25%
and 5% of prostate cancers, respectively (Barbieri et al, 2012).
These events appear anti-correlated with PTEN deletions,
supporting the notion of functional redundancy due to similar
mechanisms of action.
Cell cycle. Aberrations that drive uncontrolled cell cycling are
central to oncogenesis. Here we briefly discuss the effects of
mutations in genes that encode the retinoblastoma protein (RB1),
the p53 protein (TP53) and the v-myc myelocytomatosis viral
oncogene (MYC) in prostate cancer.
RB1 is a tumour suppressor that checks cell cycle progression
from the G1 to S cell cycle phase, and is dysfunctional in many
cancers. The RB1 gene is more commonly deleted or mutated in
castration-resistant prostate cancer (up to 45% of patients) than in
clinically localised prostate cancer, and is coincident with the
emergence of castrate-resistant disease (Taylor et al, 2010; Grasso
et al, 2012).
The TP53 protein activates expression of the p21WAF1 cyclin-
dependent kinase inhibitor, regulating the cell cycle and acting as a
classic tumour suppressor. In mouse models of prostate cancer,
inactivation of TP53 is necessary to bypass the cellular senescence
mechanisms that are activated upon the loss of PTEN (Chen et al,
2005). Aberrations in TP53 are recurrently seen in both clinically
localised, as well as advanced cancer.
The MYC proto-oncogene encodes a transcription factor that
causes oncogenesis through cycle progression and cell survival.
Amplification and to a lesser extent, mutation of MYC are
common in prostate cancer, although MYC is also often
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differentially expressed in the absence of any mutation (Shen and
Abate-Shen, 2010; Taylor et al, 2010; Barbieri et al, 2012; Grasso
et al, 2012). Often amplification is non-specific, involving a gain of
the entire arm of chromosome 8, such that this mutation may
increase expression of other oncogenes to confer a growth
advantage.
MAPK/ERK pathway. The MAPK/ERK pathway has a central
role in many cancers, though its role in prostate cancer is less well
established. The pathway is frequently perturbed in advanced
prostate cancers (Taylor et al, 2010) and may enhance transcrip-
tional activity of the AR. Activating mutations in KRAS and BRAF
occur in roughly 10% of Asian patients but are rare in Caucasian
men (Taylor et al, 2010; Barbieri et al, 2012; Grasso et al, 2012).
CONCLUSIONS
We have summarised common aberrations that contribute to the
mutational landscape of human prostate cancer. The landscape
encompasses inherited variants and mutational processes, differ-
ences in ETS family fusion-positive and -negative tumours, and the
aberrations that may go on to cause metastatic and castrate-
resistant disease.
Significant challenges impeding the application of genomic
medicine in prostate cancer include high levels of intra-tumoural
heterogeneity and multifocality in primary tumours, and the often
long natural history from diagnosis to metastasis or lethality. Both
of these challenges hinder the generation of risk-stratification tools
that correlate clinical outcomes with the genomic landscape. As
structural variants contribute greatly to the genomic landscape, we
envisage that multi-region whole-genome sequencing of hundreds
of tumours will be required to better understand the natural
evolution of prostate cancer. These methods may then pave the
way to the generation of an affordable, prompt, genomic-based
screening and treatment strategy from the clinic.
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